You are in:
Home/ Patients and Public/ Access to Information/ FOI Disclosure Log/ FOI 6313 - Multiple Sclerosis and Drugs treated

FOI 6313 - Multiple Sclerosis and Drugs treated

Date: 20 October 2020 to 20 October 2023

How many patients have been treated with the following drugs (for any disease) in the past 6 months:

  • Ampyra (dalfampridine)
  • Aubagio (teriflunomide)
  • Avonex (interferon beta-1a)  
  • Betaferon (interferon beta-1b)  
  • Brabio (glatiramer acetate) 
  • Copaxone (glatiramer acetate)  
  • Extavia (beta interferon-1b)  
  • Gilenya (fingolimod)  
  • Lemtrada (alemtuzumab)  
  • Mavenclad (cladribine) 
  • Mayzent (siponimod)
  • Ocrevus (ocrelizumab) 
  • Plegridy (peginterferon beta-1a) 
  • Rebif (beta interferon-1a)  
  • Tecfidera (dimethyl fumarate)  
  • Tysabri (natalizumab)  
  • Vumerity (diroximel fumarate) 
  • Zeposia (ozanimod)

 

  1. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:
  • Relapsing remitting MS (RRMS)
  • Secondary progressive MS (SPMS)
  • Primary progressive MS (PPMS)
  • Multiple Sclerosis - any type
  • Request ID:
    6313
  • Category:
    Clinical - Drugs
  • Response:

    October 2020

    Thank you for your recent request under the Freedom of Information Act 2000.

    The information you have requested is as follows:

    How many patients have been treated with the following drugs (for any disease) in the past 6 months:

    • Ampyra (dalfampridine)
    • Aubagio (teriflunomide)
    • Avonex (interferon beta-1a)  
    • Betaferon (interferon beta-1b)  
    • Brabio (glatiramer acetate) 
    • Copaxone (glatiramer acetate)  
    • Extavia (beta interferon-1b)  
    • Gilenya (fingolimod)  
    • Lemtrada (alemtuzumab)  
    • Mavenclad (cladribine) 
    • Mayzent (siponimod)
    • Ocrevus (ocrelizumab) 
    • Plegridy (peginterferon beta-1a) 
    • Rebif (beta interferon-1a)  
    • Tecfidera (dimethyl fumarate)  
    • Tysabri (natalizumab)  
    • Vumerity (diroximel fumarate) 
    • Zeposia (ozanimod)

    Please see below table, Please note If the drug name is not listed it is because it has not been issued.

     

    Drug Name

    Number of Patients

    HOMECARE DIMETHYL FUMARATE (SKILARENCE) G.R. 120 mg Tablets

    <5

    HOMECARE DIMETHYL FUMARATE (SKILARENCE) G.R. 30 mg Tablets

    <5

    HOMECARE DIMETHYL FUMARATE (TECIFIDERA) G.R. 120 mg Capsules

    8

    HOMECARE DIMETHYL FUMARATE (TECIFIDERA) G.R. 240 mg Capsules

    119

    HOMECARE GLATIRAMER ACETATE (COPAXONE) 20 mg in 1ml Pre-filled Syringe

    2

    HOMECARE GLATIRAMER ACETATE (COPAXONE) 40 mg in 1ml Pre-filled Syringe

    14

    HOMECARE INTERFERON BETA 1a (AVONEX) 6 million units Pre-filled Pen

    21

    HOMECARE INTERFERON BETA 1a (AVONEX) 6 million units Pre-filled Syringe

    11

    HOMECARE INTERFERON BETA 1B (BETAFERON 9.6MU) 250 microgram Injection

    <5

    HOMECARE INTERFERON BETA-1a ( REBIF via REBISMART) 22 micrograms in 0.5ml Pre-filled Pen

    <5

    HOMECARE INTERFERON BETA-1a ( REBIF via REBISMART) 44 micrograms in 0.5ml Solution for Injection

    18

    HOMECARE TERIFLUNOMIDE (AUBAGIO) 14 mg Tablets

    42

    NATALIZUMAB 300 mg in 15ml Concentrate for I/V Infusion

    16

    PEGINTERFERON ALFA-2a 90 microgram Injection

    <5

     

    1. How many patients have been treated in the past 6 months for the following types of multiple sclerosis
    • Relapsing remitting MS (RRMS)
    • Secondary progressive MS (SPMS)
    • Primary progressive MS (PPMS)
    • Multiple Sclerosis - any type

     

    Medway Foundation Trust regret that MS only has one code and we are unable to define the stage however we can confirm that 174 patients have been treated in the last 6 months for multiple sclerosis.